biotech

Money background. Close-up.

Can Aldeyra Therapeutics Shares Double?

Most investors see analysts issue Buy and Outperform ratings with 8% to 20% upside for traditional Dow Jones Industrial Average or S&P 500 stocks. Still, other analyst calls reach much ...
Read Full Story »
biotech

What Celgene Now Means for Juno

As the health care sector remains hot, it is logical to expect ongoing mergers and acquisitions action to continue. Then there are the collaborative efforts within the sector that should continue. ...
Read Full Story »
biotech

Sarepta Takes Its Foot off the Gas

Considering that a Greek exit might be on the way, the broad markets have sold off a fair amount, and across the markets companies are losing out. Sarepta Therapeutics Inc. ...
Read Full Story »
Chaparral_Supercell

Can Celladon Weather the Storm?

Celladon Corp. (NASDAQ: CLDN) has taken the long way down. Only recently has it begun to pursue options for a potential merger or sale, but it may be too late ...
Read Full Story »
Biotechnology word cloud

CAR T-Cell Stocks a Better Way to Leverage Biotech Than New 3x ETFs

If you missed the biotech run and want to try to catch the train this late in the game, it would be wise not to use the new Proshares leveraged ...
Read Full Story »
DNA

Short Sellers Get More Selective on Big Biotech

The short interest data are out for the June 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
IPO

Ritter Debuts Quietly in IPO Launch

Ritter Pharmaceuticals Inc. (NASDAQ: RTTR) is the latest company to join in on the wave of initial public offerings. In fact, there were 14 or 15 deals on deck to ...
Read Full Story »
Biotechnology word cloud

Triple Leverage ETFs Launched in Biotech

There is a new way to trade biotech out there now. For active traders and investors looking for juiced up returns in the hot biotech sector, ProShares has launched two ...
Read Full Story »
generic drugs

Oral Testosterone Pill Could Make Lipocine Worth Substantially More

Lipocine Inc. (NASDAQ: LPCN) may have a huge hit on its hands with the first swallowable oral testosterone treatment. This could revolutionize the testosterone market because users generally have to ...
Read Full Story »
IPO

Benitec From Australia Files for US IPO: Gene Silencing and Gene Therapy

Benitec Biopharma Ltd. has filed for an initial public offering in the United States. This Australian company has filed to sell American depositary shares (ADSs), with each ADS representing 20 ...
Read Full Story »
buy sell

3 Drivers Supporting BioMarin

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has three key drivers helping out its shares on Thursday. The first is solid news on its drug aimed at dwarfism. The second driver is ...
Read Full Story »
Eli Lilly Logo

Key Analyst Sees Solid Upside in Eli Lilly

Eli Lilly & Co. (NYSE: LLY) has made a big splash in the market over the past year. A key analyst sees this trend continuing despite some potential near-term headwinds. ...
Read Full Story »
investor research

Why This Analyst Sees Synergy Pharma Still Doubling Even After Huge Gains

Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) had an absolutely enormous day on Wednesday. News of its constipation drug study sent shares up 68% to $7.78 on a whopping 64 million shares. ...
Read Full Story »
health care

Is Sunesis Coming Back From the Dead?

Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) was making moves as the week drew to a close. This company was part of the red-hot health care sector, but it really did not ...
Read Full Story »
Biotechnology word cloud

Short Sellers Lose Some Conviction Against Big Biotech

The short interest data are out for the May 29 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »